newsfilter
← Latest News
GlobeNewswire·

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apellis receives up